MTL STING
Alternative Names: MTL-STINGLatest Information Update: 27 Apr 2022
At a glance
- Originator MiNA Therapeutics; University of California at San Francisco; University of Texas Southwestern Medical Center
- Developer MiNA Therapeutics
- Class Antineoplastics; Oligonucleotides; RNA
- Mechanism of Action RNA stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours